Annual report pursuant to Section 13 and 15(d)

Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)

Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands				12 Months Ended
	Jul. 01, 2022	Apr. 06, 2021	Oct. 20, 2020	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2021	Jun. 30, 2022
Goodwill				$ 872,737	$ 872,737	$ 843,067	$ 822,101
Cash paid, net of cash acquired					101,184	225,352
Namocell Inc
Current assets, net of cash	$ 3,248			3,248	3,248
Equipment and other long-term assets	405			405	405
Goodwill	51,051			51,257	51,257
Total assets acquired	130,304			130,510	130,510
Liabilities	546			546	546
Deferred income taxes, net	17,974			18,180	18,180
Net assets acquired	111,784			111,784	111,784
Cash paid, net of cash acquired	101,184			101,184
Contingent consideration payable	10,600			10,600
Net assets acquired	111,784			111,784
Total assets acquired, adjustments				206
Deferred income taxes, net, adjustments				206
Business Combination, Provisional Information [Abstract]
Adjustments to fair value, Goodwill				206
Total assets acquired, adjustments				206
Deferred income taxes, net, adjustments				206
Namocell Inc \| Developed technology
Intangible assets	73,900			73,900	73,900
Namocell Inc \| Customer relationships
Intangible assets	900			900	900
Namocell Inc \| Trade names
Intangible assets	700			700	700
Namocell Inc \| Non-competition agreement
Intangible assets	$ 100			$ 100	$ 100
Eminence Biotechnology
Current assets, net of cash						3,145
Equipment and other long-term assets						1,639
Goodwill						7,848
Total assets acquired						21,543
Liabilities						1,436
Deferred income taxes, net						1,357
Net assets acquired						18,750
Cash paid, net of cash acquired			$ 9,800			9,765
Contingent consideration payable						8,985
Net assets acquired						18,750
Eminence Biotechnology \| Developed technology
Intangible assets						6,778
Eminence Biotechnology \| Customer relationships
Intangible assets						2,133
Asuragen, Inc.
Current assets, net of cash						10,422
Equipment and other long-term assets						3,762
Goodwill						90,563
Total assets acquired						249,147
Liabilities						4,963
Deferred income taxes, net						10,297
Net assets acquired						233,887
Cash paid, net of cash acquired		$ 216,000				215,587
Contingent consideration payable						18,300
Net assets acquired						233,887
Asuragen, Inc. \| In Process Research and Development [Member]
In-process research and development						22,700
Asuragen, Inc. \| Developed technology
Intangible assets						107,000
Asuragen, Inc. \| Customer relationships
Intangible assets						11,700
Asuragen, Inc. \| Trade names
Intangible assets						2,000
Asuragen, Inc. \| Non-competition agreement
Intangible assets						$ 1,000